Dysport® should be injected at the recommended dose, in the approved muscles, by appropriately trained physicians. For every Dysport® injection, dosing should be tailored to the individual based on the size, number and location of muscles, severity of spasticity, the presence of local muscle weakness, and the patient’s response to previous treatment and/or adverse event history with botulinum toxins.1
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex)
Dosing and administration
The dosing recommendations in the Dysport® SmPC should always be followed:1
|
UPPER LIMB: A maximum total dose of Dysport® per treatment session of 16 U/kg or 640 U (whichever is lower) when injecting unilaterally, or 21 U/kg or 840 U (whichever is lower) when injecting bilaterally. Dysport® treatment may be repeated when the effect of the previous treatment had diminished, but not before 16 weeks after the previous injection. |
| DYNAMIC EQUINUS FOOT DEFORMITY: A maximum total dose of Dysport® administered per treatment session of 15 U/Kg when injecting unilaterally, or 30 U/kg when injecting bilaterally. The total Dysport® dose per treatment session must not exceed 1000 U or 30 U/kg, whichever is lower. Dysport® treatment may be reported when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection. No more than 0.5 mL should be administered at any single injection site. |
The recommended doses per treatment session for each upper limb and lower limb muscle group can be viewed in the administration guide below.
Reference:
- Dysport® Summary of Product Characteristics.
Abbreviations:
SmPC, Summary of Product Characteristics; U, units.
For further information, please refer to the Prescribing Information or the Summary of Product Characteristics.